140 results about "Roflumilast" patented technology

An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.

The invention discloses a preparation method and a detection method of a roflumilast material. The preparation method comprises the following steps: mixing 3-cyclopropyl methoxy group-4-difluoro methoxy group benzoic acid SM-1, thionyl chloride, dimethyl formamide with toluene, and carrying out an acylating chlorination reaction to obtain a midbody 1; mixing 3,5-dichloro-4-aminopyridine SM-2, tetrahydrofuran with potassium tert-butoxide and carrying out a salt forming reaction to obtain tetrahydrofuran solution of a midbody 2; and then mixing the midbody 1 and the midbody 2 with tetrahydrofuran, carrying out amidation to obtain a crude product of roflumilast, and refining the crude product of roflumilast to prepare the roflumilast material. Aiming to overcome the shortage of the prior art, the preparation process of the roflumilast material is optimized, so that the curative effect for treating diseases such as chronic obstructive pulmonary disease (COPD) is more remarkable; and besides, a systematic, complete and effective composition identifying and content measuring method is provided, so that the quality of the medicine can be effectively controlled, and the clinical effect is ensured.

The invention relates to a new roflumilast intermediate compound and a preparation method thereof, and application of the intermediate compound in preparing roflumilast. The roflumilast prepared from the intermediate has the advantages of mild reaction conditions, low requirements for reaction conditions and equipment, fewer byproducts, high product purity and yield and low production cost, does not use palladium on carbon, carbon monoxide or any other high-cost high-toxicity reagent, and is suitable for large-scale industrial production.

The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of roflumilast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

The invention discloses a method for preparing high-purity roflumilast which is a compound as shown in the formula (I). The compound is an orally taken selective phosphodiesterase 4 (PDE4) inhibitor and is proven to be capable of inhibiting inflammation related to a chronic obstructive pulmonary disease (COPD).

The application belongs to the field of medicines, and in particular relates to a roflumilast solid dispersoid and a preparation method thereof as well as a roflumilast preparation. The roflumilast solid dispersoid provided by the application comprises the following components in parts by weight: 1 part of roflumilast and 3-10 parts of a carrier, wherein the carrier is copovidone, poloxamer or polyethylene glycol. The roflumilast preparation provided by the invention comprises the following components in parts by weight: 0.4-12 parts of a solid dispersoid and 5-95 parts of a filling agent. Experiment results show that the 30-minute dissolution rate of the roflumilast solid dispersoid provided by the application is more than 96%; and the 30-minute dissolution rate of the roflumilast preparation provided by the invention is more than 98%, and the biological availability is more than 75%.

The invention belongs to the field of medicine technology, and relates to an orally disintegrating tablet comprising roflumilast and a preparation method of the orally disintegrating tablet. The orally disintegrating tablet comprises roflumilast, a hydrophilic filler, a water-soluble polymer adhesive, a disintegrating agent, a flavouring agent, a lubricant, and the like. The objective of the invention is to provide the roflumilast orally disintegrating tablet that has advantages of simple preparation technology, taking convenience, rapid effect, rapid concentration peak and obvious curative effects.

The invention provides a roflumilast oral preparation and a preparation method thereof. According to the invention, solvent solid dispersion technology is adopted, and the solid oral preparation is prepared by 0.1-50 wt% of roflumilast and 50-99.9 wt% of pharmaceutically acceptable auxiliary materials. Roflumilast tablets with stable and controllable quality can be produced by using common pharmaceutical equipment, which is helpful for vast patients to obtain cheap and good medicine products.

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

The invention discloses a compound aerosol for quick-acting treatment of COPD, and a preparation method thereof. The compound aerosol comprises roflumilast and salbutamol. The compound aerosol combines respective characteristics of the long-acting COPD medicine roflumilast and the quick-acting COPD medicine salbutamol, and realizes rapid effectiveness and long lasting time in order to reduce the oral spray frequency of patients and reduce toxic side effects. A propellent changes from CFCs to HFC in order to eliminate destroys to the earth's ozone layer. Lecithin selected in the invention is in favor of realizing immersion and penetration of medicines to lung cells in order to improve the bioavailability and realize quick acting. Mentholum is added into a dispersant, so the patients have refreshing and comfortable feeling after administration, thereby the patients' compliance is improved.

The invention discloses a roflumilast tablet and a preparation method thereof. The roflumilast tablet is composed of roflumilast, starch, pregelatinized starch, lactose, PVP-K90 and magnesium stearate. According to the preparation method, roflumilast is dissolved in anhydrous ethanol, so that the bulk drug is dispersed in an excipient in a solution form; and the release rate of the tablet in four media with different pH is regulated by specific proportions of the starch to the pregelatinized starch, so that the roflumilast tablet has good release curve and good content uniformity in the four media. The preparation method is simple and convenient in process; the bulk drug is in no need of micronization treatment; and the preparation method is in no need of special equipment, can be industrialized easily, is high in product yield, and has obvious advantages.

The invention discloses a method for preparing a Roflumilast raw material and intermediates. The method includes steps as follows:, 4-difluoromethoxy-3-hydroxy benzaldehyde reacts with cyclopropylmethylbromide under the conditions of solvent and catalytic agents, and then 4-difluoromethoxy-3-cyclopropyl methoxybenzaldehyde is obtained after extraction and recovery; 4-difluoromethoxy-3-cyclopropyl methoxybenzaldehyde reacts with potassium permanganate in a solvent environment, and 4-difluoromethoxy-3-cyclopropyl methoxybenzoic acid is obtained through post-processing; and 4-difluoromethoxy-3-cyclopropyl methoxybenzoic acid reacts with 4-amino-3,5-dichloropyridine under the conditions of solvent and thionyl chloride, and crude Roflumilast products are obtained through post-processing. The method has the advantages of skillful concept, simple process, low manufacturing cost, high product yield coefficient and no generation of harmful gas.